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Protection against hepatitis E virus infection by naturally acquired and vaccine-induced
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Abstract
Immunity acquired from infection or vaccination protects humans from symptomatic hepatitis E. However, whether the risk of hepatitis E
virus (HEV) infection is reduced by the immunity remains unknown. To understand this issue, a cohort with 12 409 participants randomized
to receive the hepatitis E vaccine Hecolin or placebo were serologically followed up for 2 years after vaccination. About half (47%) of
participants were initially seropositive. A total of 139 infection episodes, evidenced by four-fold or greater rise of anti-HEV level or positive
seroconversion, occurred in participants who received three doses of treatment. Risk of infection was highest among the baseline
seronegative placebo group participants (2.04%). Pre-existing immunity and vaccine-induced immunity lower the risk signiﬁcantly, to 0.52%
and 0.30%, respectively. In conclusion, both vaccine-induced and naturally acquired immunity can effectively protect against HEV infection.
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Abstract
Genital warts (GWs) and laryngeal papillomatosis (LP) are two usually benign pathologies related to infection with human papillomaviruses
(HPVs), mainly HPV6 and HPV11. The aim of this work was to describe the genetic diversity of HPV6 and HPV11 isolates found in GWs and
LPs, and to analyse the differential involvement of viral variants in either lesion. A total of 231 samples diagnosed as GWs (n = 198) or LP
(n = 33) and caused by HPV6 or HPV11 monoinfections were analysed. The phylogenetic relationships of the retrieved viral sequences
were explored. We have identiﬁed the long control region and the intergenic E2–L2 region as the two most variable regions in both HPV6
and HPV11 genomes. We have generated new HPV6 (n = 166) or HPV11 (n = 65) partial sequences from GWs and LPs lesions spanning
both regions and studied them in the context of all available sequences of both types (ﬁnal n = 412). Our results show a signiﬁcant (p <0.01)
differential presence of HPV6 variants among both pathologies, with HPV6 B variants being preferentially found in GW versus LP samples.
No differential involvement of HPV11 variants was observed. Our ﬁndings suggest that different HPV6 variants may either show differential
tropism or have different potential to induce lesions in different epithelia.
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